Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENNVAX-GP and IL-12 DNA Vaccine for HIV
NCT02431767Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2015
- Primary completion
- Jun 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PENNVAX-GP in human immunodeficiency virus infection (HIV) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency and severity of reactogenicity signs and symptoms at Month 18, Magnitude of local injection/EP site pain at Month 18 and 4 more. Started Aug 2015; status: completed.
02
Drugs
PENNVAX-GP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02431767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431767.